CRC Research Update — August 09, 2026
Today's colorectal cancer research highlights
Archive
A collection of 422 issues
Latest
ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer
Skip to content
The CRC Digest
ctDNA-Guided Treatment Decisions Show Mixed Results in Stage II and III Colon Cancer
DYNAMIC-III found that escalation in ctDNA-positive stage III patients did not improve outcomes. (EClinicalMedicine)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care
Early Palliative Care Contact Linked to Reduced End-of-Life Healthcare Use
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Early Palliative Care Contact Linked to Reduced End-of-Life Healthcare Use
A nationwide Finnish study found that early specialist palliative care involvement (more than 30 days before death) was associated with lower healthcare utilization at end of life in patients with colorectal
Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC
Skip to content
The CRC Digest
▸ TREATMENT
Study Evaluates Trifluridine/Tipiracil in MSI-H/dMMR Metastatic CRC
A study across 10 Japanese hospitals aimed to evaluate trifluridine/tipiracil (with or without bevacizumab) in MSI-H/dMMR metastatic colorectal cancer, a population known to resist standard fluorouracil-based therapies. (Therapeutic Advances in Medical Oncology)
ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection
Skip to content
The CRC Digest
◇ RESEARCH
ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection
A review of circulating tumor DNA in GI cancers found that while postoperative ctDNA positivity identifies high-risk patients, recent trials show mixed results: DYNAMIC-III showed escalation in ctDNA-positive stage III disease
13-Year NordICC Data Show Colonoscopy Reduces CRC Incidence but Not Mortality
Skip to content
The CRC Digest
▪ SCREENING
13-Year NordICC Data Show Colonoscopy Reduces CRC Incidence but Not Mortality
Long-term follow-up from the NordICC trial comparing colonoscopy to no screening found a reduction in colorectal cancer incidence but no statistically significant mortality benefit at 13 years. (Gastroenterology)
This content is informational
CRC Research Update — August 08, 2026
Today's colorectal cancer research highlights
NCI-MATCH trial analysis compares tumor genomic alterations in adolescents and young adults versus older patients
Skip to content
The CRC Digest
NCI-MATCH trial analysis compares tumor genomic alterations in adolescents and young adults versus older patients
Analysis of 759 colorectal cancer patients from the NCI-MATCH trial compared genomic profiles between AYAs (18-39 years, n=43) and non-AYAs (40+ years) using a 143-gene panel. (JCO Precision
Review links colibactin-producing E. coli to early-onset colorectal cancer through distinct mutational signatures
Skip to content
The CRC Digest
◇ RESEARCH
Review links colibactin-producing E. coli to early-onset colorectal cancer through distinct mutational signatures
Genomic profiling has identified mutational signatures SBS88 and ID18 in colorectal tumors exposed to colibactin from pks+ E. coli, with emerging data suggesting enrichment in early-onset CRC. (Infection, Genetics and
Study identifies distinct stigma profiles among colorectal cancer patients with ostomies
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Study identifies distinct stigma profiles among colorectal cancer patients with ostomies
A cross-sectional survey of 449 patients with colorectal cancer and intestinal ostomy used latent profile analysis to identify stigma subtypes and found that stoma acceptance mediates the relationship between stigma
AI method for classifying pathology whole slide images using self-distillation technique
Skip to content
The CRC Digest
◇ RESEARCH
AI method for classifying pathology whole slide images using self-distillation technique
Researchers developed a phenotypic self-distillation approach to classify whole slide images in colorectal cancer, addressing limitations of current attention mechanisms in Multiple Instance Learning. (Pathology Research and Practice)
This content is informational
13-year NordICC trial data
Skip to content
The CRC Digest
▪ SCREENING
13-year NordICC trial data
(Gastroenterology)
This content is informational only and does not constitute medical advice.
Always consult your oncologist or care team.
© 2026 The CRC Digest —
crcdigest.com
KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients
Skip to content
The CRC Digest
KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients
A retrospective study investigated the distribution of specific KRAS mutation sites and their associations with clinicopathological parameters and survival outcomes. (Zhong Nan Da Xue Xue Bao Yi Xue Ban)
This content is informational only
Dementia Linked to Lower Surgery Rates and Survival in Stage I-III Colorectal Cancer
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Dementia Linked to Lower Surgery Rates and Survival in Stage I-III Colorectal Cancer
Analysis of the Indiana Cancer Registry found that patients with dementia and stage I-III colorectal cancer have increased mortality and receive less invasive evaluations and surgery, with surgery
Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery
Skip to content
The CRC Digest
▸ TREATMENT
Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery
A multicenter study of 3,385 rectal cancer patients aimed to compare short-term recovery, 6-month functional outcomes, and long-term survival among natural orifice specimen extraction surgery, laparoscopic surgery, and open surgery. (Diseases of
ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer
Comprehensive genomic profiling of 56,206 advanced colorectal tumors characterized the prevalence and therapeutic implications of ALK fusions, which are established targets in lung cancer but rare in CRC. (The Oncologist)
This
COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer
A new analysis examines what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. (Journal of Clinical Oncology)
CRC Research Update — August 07, 2026
Today's colorectal cancer research highlights
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
Skip to content
The CRC Digest
Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease
A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant
Direct visualization system aids stent placement in 39-year-old with malignant obstruction
Skip to content
The CRC Digest
Direct visualization system aids stent placement in 39-year-old with malignant obstruction
A case report describes successful use of a direct visualization device to guide enteral stent placement across a stenotic sigmoid colon tumor in a 39-year-old woman with intestinal obstruction. (Frontiers in Medicine)
This